A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA)
Giuseppe Fornarini, Sara Elena Rebuzzi, Sebastiano Buti, Pasquale Rescigno, Axel Merseburger, Ugo de Giorgi, Umberto Basso, Marco Maruzzo, Patrizia Giannatempo, Marta Ponzano, Emilio Francesco Giunta, Fabio Catalano, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Miguel Angel Llaja Obispo, Alessio Signori, Giuseppe Luigi Banna
doi: https://doi.org/10.1101/2022.08.30.22279352
Giuseppe Fornarini
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Sara Elena Rebuzzi
2Medical Oncology Unit, Ospedale San Paolo, Savona, Italy
3Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy
Sebastiano Buti
4Medical Oncology Unit, University Hospital of Parma, Parma, Italy
5Medicine and Surgery Department, University of Parma, Parma, Italy
Pasquale Rescigno
6Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy
Axel Merseburger
7Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany
Ugo de Giorgi
8Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Meldola, Italy
Umberto Basso
9Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy
Marco Maruzzo
9Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy
Patrizia Giannatempo
10Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Marta Ponzano
11Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy
Emilio Francesco Giunta
8Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Meldola, Italy
Fabio Catalano
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Veronica Murianni
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Alessandra Damassi
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Malvina Cremante
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Annalice Gandini
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Silvia Puglisi
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Miguel Angel Llaja Obispo
1Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Alessio Signori
11Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy
Giuseppe Luigi Banna
12Department of Oncology, Portsmouth Hospitals University NHS Trust, PO6 3LY, Portsmouth, UK
Data Availability
Data availability is subject to a written request to Roche.
Posted September 05, 2022.
A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA)
Giuseppe Fornarini, Sara Elena Rebuzzi, Sebastiano Buti, Pasquale Rescigno, Axel Merseburger, Ugo de Giorgi, Umberto Basso, Marco Maruzzo, Patrizia Giannatempo, Marta Ponzano, Emilio Francesco Giunta, Fabio Catalano, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Miguel Angel Llaja Obispo, Alessio Signori, Giuseppe Luigi Banna
medRxiv 2022.08.30.22279352; doi: https://doi.org/10.1101/2022.08.30.22279352
A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA)
Giuseppe Fornarini, Sara Elena Rebuzzi, Sebastiano Buti, Pasquale Rescigno, Axel Merseburger, Ugo de Giorgi, Umberto Basso, Marco Maruzzo, Patrizia Giannatempo, Marta Ponzano, Emilio Francesco Giunta, Fabio Catalano, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Miguel Angel Llaja Obispo, Alessio Signori, Giuseppe Luigi Banna
medRxiv 2022.08.30.22279352; doi: https://doi.org/10.1101/2022.08.30.22279352
Subject Area
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (624)
- Anesthesia (162)
- Cardiovascular Medicine (2335)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11696)
- Forensic Medicine (10)
- Gastroenterology (693)
- Genetic and Genomic Medicine (3679)
- Geriatric Medicine (345)
- Health Economics (630)
- Health Informatics (2362)
- Health Policy (925)
- Hematology (339)
- HIV/AIDS (772)
- Medical Education (363)
- Medical Ethics (104)
- Nephrology (396)
- Neurology (3438)
- Nursing (194)
- Nutrition (519)
- Oncology (1800)
- Ophthalmology (533)
- Orthopedics (217)
- Otolaryngology (285)
- Pain Medicine (230)
- Palliative Medicine (66)
- Pathology (444)
- Pediatrics (1021)
- Primary Care Research (415)
- Public and Global Health (6084)
- Radiology and Imaging (1254)
- Respiratory Medicine (821)
- Rheumatology (375)
- Sports Medicine (320)
- Surgery (396)
- Toxicology (50)
- Transplantation (171)
- Urology (144)